Neel M. Shah, Mohamed Teleb, Miraie Wardi, Hasan J. Salameh
Department of Internal Medicine, Texas Tech University Health Sciences Center (TTUHSC), Paul L. Foster School of Medicine, El Paso, TX, USA
Med Sci Rev 2015; 2:137-142
Despite advancements in medicine, hyperkalemia has remained a dangerous electrolyte imbalance disorder without new pharmaceutical agents for chronic treatment. Currently, agents that help treat hyperkalemia are for acute onset, and no long-term treatments with sufficient efficacy and safety are available. This review examines patiromer, which is currently pending U. S. Food and Drug Administration (FDA) approval, regarding ability to decrease mean serum potassium levels in patients with chronic kidney disease (CKD) while taking renin-angiotensin-aldosterone system inhibitors (RAASi). The review will also examine the long-term safety of this drug for potential long-term management. Published articles were found using a national database that pertained only to patiromer and hyperkalemia in CKD patients. We excluded any trials that looked at hyperkalemia in primarily heart failure. The present study takes an in-depth look at how the drug performed in 3 consecutive trials and summarizes them in a single article for reader convenience. Overall, patiromer shows promising evidence in clinical trials to provide a decrease in mean serum potassium and has a relatively mild side effect panel over a chronic treatment phase. Further trials should be performed to test these results over a multiracial and multi gender population.
Keywords: Angiotensin-Converting Enzyme Inhibitors, Hyperkalemia, Renal Insufficiency, Chronic